Lifelong and expensive immunoglobulin administration is the main therapy for chronic dysimmune polyneuropathies as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN). Based on recent clinical evidence, this treatment can be administered by intravenous immunoglobulin (IVIg) or subcutaneous infusions (SCIg) and delivered at home. IVIg, in responsive and stabilized patients, is usually administered in an outpatient setting with twice a month infusion every 25–35 days (1–2 g/Kg/month). Conversely, SCIg is given at home in most cases with three to five weekly infusions (1–2 g/Kg/month). This study aims to determine whether SCIg is cost-effective compared with IVIg from a regional health service perspective. First, costs were calculated through simulation testing different hypotheses on cost drivers. Secondly, costs were estimated on the basis of field data collected from our patients. We considered only direct medical costs. The results of the simulation show that the yearly direct costs to treat a patients were € 43,456 (IVIg) and € 42,772 (SCIg). Ig acquisition costs were the main cost driver; it represented respectively 97% (SCIg) and 93% (IVIg) of the total cost. 3%only is due to the cost of medical and nursing staff (IVIg) and 3% is due to the cost of IVIg’s side effect treatment: this cost is absent for SCIg. Estimation made from the field data were found to be little different: over 6 months the total mean cost was € 21,088 (IVIg) and € 20,878 (SCIg). Our pilot study documents the existence of two treatments, SCIg and IVIg, substantially equivalent as efficacy and costs for treating chronic dysimmune neuropathies.

Economic evaluation of different modalities of immunoglobulin therapy in chronic dysimmune polyradiculoneuropathies

MILLA, Paola;CATTEL, Luigi
2012-01-01

Abstract

Lifelong and expensive immunoglobulin administration is the main therapy for chronic dysimmune polyneuropathies as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN). Based on recent clinical evidence, this treatment can be administered by intravenous immunoglobulin (IVIg) or subcutaneous infusions (SCIg) and delivered at home. IVIg, in responsive and stabilized patients, is usually administered in an outpatient setting with twice a month infusion every 25–35 days (1–2 g/Kg/month). Conversely, SCIg is given at home in most cases with three to five weekly infusions (1–2 g/Kg/month). This study aims to determine whether SCIg is cost-effective compared with IVIg from a regional health service perspective. First, costs were calculated through simulation testing different hypotheses on cost drivers. Secondly, costs were estimated on the basis of field data collected from our patients. We considered only direct medical costs. The results of the simulation show that the yearly direct costs to treat a patients were € 43,456 (IVIg) and € 42,772 (SCIg). Ig acquisition costs were the main cost driver; it represented respectively 97% (SCIg) and 93% (IVIg) of the total cost. 3%only is due to the cost of medical and nursing staff (IVIg) and 3% is due to the cost of IVIg’s side effect treatment: this cost is absent for SCIg. Estimation made from the field data were found to be little different: over 6 months the total mean cost was € 21,088 (IVIg) and € 20,878 (SCIg). Our pilot study documents the existence of two treatments, SCIg and IVIg, substantially equivalent as efficacy and costs for treating chronic dysimmune neuropathies.
RATIONALIZATION FOR HIGH-COST DRUGS
Torino, Italy
5 ottobre 2012
RATIONALIZATION FOR HIGH-COST DRUGS
Azygos srl
10
10
Pharmacoeconomics; chronic dysimmune polyneuropathies; immunoglobulin administration
D. Cocito; G. Serra; I. Paolasso; Y. Falcone; D.A. Barilà; P. Milla; L. Cattel
File in questo prodotto:
File Dimensione Formato  
Pagina 10 da abstract_spesa_farmaci.pdf

Accesso aperto

Tipo di file: MATERIALE NON BIBLIOGRAFICO
Dimensione 109.49 kB
Formato Adobe PDF
109.49 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/119888
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact